Name | Number of supported studies | Average coverage | |
---|---|---|---|
retinal ganglion cell | 4 studies | 67% ± 26% | |
glutamatergic neuron | 3 studies | 43% ± 17% | |
club cell | 3 studies | 21% ± 4% | |
respiratory goblet cell | 3 studies | 46% ± 21% |
Insufficient scRNA-seq data for expression of LYNX1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 12649.54 | 2637 / 2642 | 99% | 60.39 | 699 / 705 |
adrenal gland | 99% | 5042.63 | 256 / 258 | 96% | 37.76 | 220 / 230 |
prostate | 98% | 3645.38 | 240 / 245 | 94% | 12.10 | 474 / 502 |
liver | 89% | 2951.44 | 201 / 226 | 86% | 25.93 | 351 / 406 |
uterus | 97% | 3940.04 | 165 / 170 | 69% | 14.27 | 319 / 459 |
thymus | 77% | 1640.51 | 504 / 653 | 89% | 19.22 | 538 / 605 |
esophagus | 99% | 10044.71 | 1434 / 1445 | 46% | 5.38 | 85 / 183 |
kidney | 75% | 1888.34 | 67 / 89 | 64% | 8.93 | 581 / 901 |
breast | 76% | 1864.20 | 348 / 459 | 61% | 10.38 | 687 / 1118 |
ovary | 86% | 2384.48 | 155 / 180 | 43% | 5.89 | 187 / 430 |
skin | 76% | 5930.07 | 1383 / 1809 | 50% | 9.06 | 236 / 472 |
lung | 68% | 1458.03 | 391 / 578 | 57% | 8.53 | 661 / 1155 |
bladder | 86% | 2863.19 | 18 / 21 | 35% | 4.04 | 178 / 504 |
eye | 0% | 0 | 0 / 0 | 100% | 33.44 | 80 / 80 |
heart | 97% | 9995.52 | 833 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 96% | 4347.60 | 1286 / 1335 | 0% | 0 | 0 / 0 |
pancreas | 10% | 183.97 | 33 / 328 | 79% | 9.11 | 140 / 178 |
spleen | 87% | 2086.56 | 210 / 241 | 0% | 0 | 0 / 0 |
intestine | 69% | 2532.87 | 665 / 966 | 14% | 1.28 | 73 / 527 |
tonsil | 0% | 0 | 0 / 0 | 73% | 9.20 | 33 / 45 |
stomach | 47% | 1578.08 | 170 / 359 | 20% | 2.22 | 57 / 286 |
adipose | 64% | 1389.54 | 774 / 1204 | 0% | 0 | 0 / 0 |
muscle | 8% | 126.24 | 61 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 1.34 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0099601 | Biological process | regulation of neurotransmitter receptor activity |
GO_0007271 | Biological process | synaptic transmission, cholinergic |
GO_0098552 | Cellular component | side of membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0045202 | Cellular component | synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0030425 | Cellular component | dendrite |
GO_0030548 | Molecular function | acetylcholine receptor regulator activity |
GO_0033130 | Molecular function | acetylcholine receptor binding |
GO_0008200 | Molecular function | ion channel inhibitor activity |
GO_0030550 | Molecular function | acetylcholine receptor inhibitor activity |
Gene name | LYNX1 |
Protein name | Ly-6/neurotoxin-like protein 1 (Endogenous prototoxin LYNX1) (Testicular tissue protein Li 112) Ly6/neurotoxin 1 Alternative protein LYNX1 |
Synonyms | |
Description | FUNCTION: Acts in different tissues through interaction to nicotinic acetylcholine receptors (nAChRs) . The proposed role as modulator of nAChR activity seems to be dependent on the nAChR subtype and stoichiometry, and to involve an effect on nAChR trafficking and its cell surface expression, and on single channel properties of the nAChR inserted in the plasma membrane. Modulates functional properties of nicotinic acetylcholine receptors (nAChRs) to prevent excessive excitation, and hence neurodegeneration. Enhances desensitization by increasing both the rate and extent of desensitization of alpha-4:beta-2-containing nAChRs and slowing recovery from desensitization. Promotes large amplitude ACh-evoked currents through alpha-4:beta-2 nAChRs. Is involved in regulation of the nAChR pentameric assembly in the endoplasmic reticulum. Shifts stoichiometry from high sensitivity alpha-4(2):beta-2(3) to low sensitivity alpha-4(3):beta-2(2) nAChR (By similarity). In vitro modulates alpha-3:beta-4-containing nAChRs. Reduces cell surface expression of (alpha-3:beta-4)(2):beta-4 and (alpha-3:beta-4)(2):alpha-5 nAChRs suggesting an interaction with nAChR alpha-3(-):(+)beta-4 subunit interfaces and an allosteric mode. Corresponding single channel effects characterized by decreased unitary conductance, altered burst proportions and enhanced desensitization/inactivation seem to depend on nAChR alpha:alpha subunit interfaces and are greater in (alpha-3:beta-2)(2):alpha-3 when compared to (alpha-3:beta-2)(2):alpha-5 nAChRs . Prevents plasticity in the primary visual cortex late in life (By similarity). . |
Accessions | ENST00000613110.4 ENST00000614268.4 ENST00000620006.4 [P0DP58-1] A0A087WZS0 L8EB58 P0DP58 ENST00000652477.1 [P0DP58-1] A0A087WYG6 ENST00000621401.4 [P0DP58-1] ENST00000614491.1 [P0DP58-1] |